Related references
Note: Only part of the references are listed.Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Claire F. Friedman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Maartje W. Rohaan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Daniel J. Olson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Ines Pires da Silva et al.
LANCET ONCOLOGY (2021)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Harriet M. Kluger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Spencer C. Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma
M. T. Tetzlaff et al.
ANNALS OF ONCOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Jason J. Luke et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Releasing the Brakes on Cancer Immunotherapy
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Lidia Robert et al.
CLINICAL CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
Edward Cha et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
Lidia Robert et al.
ONCOIMMUNOLOGY (2014)
CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
Rong Rong Huang et al.
CLINICAL CANCER RESEARCH (2011)
Imaging of CTLA4 Blockade-Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab
Antoni Ribas et al.
JOURNAL OF NUCLEAR MEDICINE (2010)